Physician profile
John D Schmidt
NPI 1336645597
$2,499.42
in general payments reported to CMS, 2019-2025
21 companies · $1,366 in 2025
The $1,366 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $134 · 2024: $1,000 · 2025: $1,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,499.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $408.02 | 2023-2025 | Airsupra, Farxiga |
| Abbvie INC. | $349.09 | 2024-2025 | |
| Novo Nordisk INC | $280.48 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $234.15 | 2024-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $208.88 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $163.18 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Exact Sciences Corporation | $151.49 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $120.44 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.63 | 2024-2025 | Xifaxan |
| Dynavax Technologies Corporation | $93.58 | 2023-2025 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $91.64 | 2024 | Voquezna |
| Pfizer INC. | $62.80 | 2024-2025 | |
| Daiichi Sankyo INC. | $50.05 | 2025 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $44.29 | 2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $32.60 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.53 | 2024 | Caplyta |
| Shield Therapeutics INC | $22.61 | 2025 | |
| Microtransponder, INC. | $19.49 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.70 | 2024 | |
| Abbott Laboratories | $15.27 | 2025 | Freestyle Libre 3 |
| Currax Pharmaceuticals LLC | $13.50 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.